Nuvalent, Inc. (NUVL)

70,88 -1,76 (-2,42%) Börsenschluss: 04:00PM EDT

Nuvalent, Inc.

One Broadway
14th Floor
Cambridge, MA 02142
United States
857 357 7000
https://www.nuvalent.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 106

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. James R. Porter Ph.D.	CEO, President & Director	1,05M	N/A	1976
Prof. Matthew D. Shair Ph.D.	Founder, Head of Scientific Advisory Board & Director	239k	N/A	1969
Ms. Alexandra Balcom CPA, M.B.A.	CFO & Treasurer	689,41k	N/A	1985
Dr. Christopher D. Turner M.D.	Chief Medical Officer	750,97k	N/A	1969
Dr. Benjamin Lane Ph.D.	Senior Vice President of Technical Operations	N/A	N/A	N/A
Ms. Deborah Ann Miller J.D., Ph.D.	Chief Legal Officer & Secretary	595,96k	N/A	1976
Mr. Matthew Metivier	Senior Vice President of Human Resources	N/A	N/A	N/A
Ms. Darlene Noci	Chief Development Officer	N/A	N/A	1978
Mr. Henry Pelish Ph.D.	Senior Vice President of Drug Discovery	N/A	N/A	N/A
Mr. John Soglia Ph.D.	Senior Vice President of Translational Development	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Nuvalent, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 9. Die grundlegenden Scores sind Audit: 8, Vorstand: 7, Shareholderrechte: 10, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.